Latest news with #Apnimed

The Risks Associated With Sleep Are Potentially Being Innovated Away

Forbes

31-07-2025

Health
Forbes

The Risks Associated With Sleep Are Potentially Being Innovated Away

Austrian School eminence Ludwig von Mises once observed that any action outside the stationary state is a speculation on what's ahead. Looked at through the prism of sleep, it's not only good for us, it's also safe. While asleep we can't exit the very stationary state that could lead to monstrous error. Just the same, readers are increasingly aware that even sleep comes with risks. Think sleep apnea. The throat muscles of some narrow during sleep. The latter can cause people to snore all the while boosting the risk of higher blood pressure, Type 2 diabetes, heart attack, and stroke. Even the good things can be risky, or so it seems. All of which speaks to the beauty of the profit motive. Problems generally rate solutions crafted by the profit-motivated, and it seems sleep apnea is the latest problem that is being met with a solution. This is important in the here and now in consideration of what's available to mitigate the health and irritability effects of fitful sleep born of sleep apnea. For now, snorers can put on a face mask at bedtime, and that is connected to a continuous positive pressure (CPAP) machine. The machine keeps the constricted airway open via air that's forced through the opening. It's known to work, but there's a discomfort quality to the machine that causes some to abandon the whole project of mitigating sleep apnea's challenges. The good news is that Cambridge, MA-based Apnimed has come up with a pre-bedtime pill that can do for sleep apnea sufferers what formerly could only be done by a mask. It's progress, which is the point. Particularly right now. Politicians, including President Trump, can't get beyond the crucial truth that market prices aren't to be lamented, rather they're to be treasured. Prices are what organized market economies, and they're in particular a crucial signal telling producers where their intrepid ways will be rewarded. The CPAP machines are quite simply not enough for sleep apnea sufferers, which explains the work being done by Apnimed to replace sleeping machines with an oral drug. For now, Apnimed's drug is in clinical trials. The New York Times has interviewed sleep doctors who believe the drug could 'transform the lives of many,' and crucially not just those who dislike the CPAP machines. Others take weight-loss drugs to fix the sleep apnea problem, not to mention the myriad other oral devices snorers purchase in hopes of snoring less while sleeping. Which is a comment that Apnimed's drug won't just potentially transform sleep health, it could also enhance life quality in the bargain. Side effects? Invariably there are some, and the Times lists dry mouth and insomnia as two. Which is yet another reason for politicians to cease trying to corrupt the brilliance of freely arrived at price signals. Figure that if Apnimed succeeds, and logically prospers by virtue of transforming sleep, health and life quality, its success will exist as a lure for others to enter the space. From this, it's no insight to suggest that increased investment will gradually not just be meant to improve on the existing drug, but erase some of the downsides of it. Investment is about improvement, and its profits that are a magnet for it. Which demands yet again that politicians stay out, and cease talk of 'most favored nations' drug prices, 'bending the cost curve' downward, or any other actions meant to obscure true prices. Market forces are routinely working to improve our health and wellbeing, so let's allow markets to work.

A pill for sleep apnea could be on the horizon

Observer

29-07-2025

Health
Observer

A pill for sleep apnea could be on the horizon

Tens of millions of people in the United States struggle with obstructive sleep apnea, a condition that occurs when the throat muscles narrow during sleep, leading to temporary pauses in breathing that can cause people to snore and jolt awake, gasping for air. Poor sleep can leave people feeling exhausted, irritable and unfocused during the day. And if left untreated, sleep apnea can increase the risk for serious conditions such as high blood pressure, Type 2 diabetes, heart attack and stroke. For decades, the primary treatment for sleep apnea has been continuous positive airway pressure (or CPAP). Before bed, those with the condition put on a face mask that is connected to a CPAP machine, which keeps the airway open by forcing air into it. The machines are effective, but many find them so noisy, cumbersome or uncomfortable that they end up abandoning them. Now, a more appealing option may be on the way, according to a news release from Apnimed, a pharmaceutical company focused on treating sleep apnea. Last week, the company announced a second round of positive Phase 3 clinical trial results for a first-of-its-kind pill that can be taken just before bedtime to help keep a person's airway open. The full results have not yet been released or published in a peer-reviewed journal. But the findings build on past, similarly positive conclusions from trials and studies. Sleep experts say that what they're seeing in reports so far makes them think the pill could be a game changer. Dr. Phyllis Zee, a sleep doctor and researcher at Northwestern Medicine who was not involved with the trial, said that if approved, the drug could transform the lives of many. That includes not only those who can't tolerate CPAP machines, but also those who can't — or prefer not to — use other interventions, such as other types of oral devices or weight loss medications. (Excess weight is a risk factor for sleep apnea.) How does the new drug work? Dr. Sanjay R. Patel, a sleep researcher at the University of Pittsburgh who led the new trial, described trying to breathe through a constricted airway like slurping soda through a soggy paper straw. 'If that straw is really floppy, then when you suck, you suck the walls shut, and you can't get any of the soda,' he said. The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the airway muscles activated throughout the night, leaving the breathing path clear. The drugs 'essentially trick those muscles into thinking they're awake,' said Dr. Daniel Combs, an associate professor of pediatrics and medicine at the University of Arizona, who was not involved with the trial but is studying a drug similar to AD109. The new trial included 660 adults with sleep apnea who either couldn't tolerate CPAP machines or refused to use them. According to Apnimed's news release, AD109 significantly reduced the average number of hourly breathing interruptions in participants who took the pill, compared with those given a placebo. Some participants who took the pill did report side effects, including dry mouth and insomnia, said Dr. Larry Miller, chief executive of Apnimed. But the company has not published detailed data about those side effects. According to Miller, just 3% of the patients who took AD109 found the insomnia significant enough to stop taking the drug. (BEGIN OPTIONAL TRIM.) Dr. Sairam Parthasarathy, a sleep researcher at the University of Arizona who was not involved with the trial, said it would be helpful to review the full data on the side effects, as well as other evidence on how well the drug works in people with chronic conditions such as heart disease or severe obesity. (People with sleep apnea often have these conditions at the same time.) It's unclear how much the drug will cost and whether insurers will cover it. Some researchers also wondered whether the drug would improve daytime fatigue and mood. Even so, it could be 'a big deal for patients,' Parthasarathy said. Many people with sleep apnea are so averse to using CPAP machines that they don't seek treatment. He said he would prescribe the drug based on the results of this trial and others. (END OPTIONAL TRIM.) Apnimed plans to share the complete data, including how well the pill reduced snoring, in October, Miller said. He added that the company intended to seek approval from the Food and Drug Administration in early 2026. Miller said he was optimistic that the clinical trial results would support an FDA approval, but if or when that might happen is unclear, especially given recent changes at the agency. Could the pill replace other sleep apnea treatments? When used properly, CPAP machines are currently the most effective option for treating sleep apnea. And many people become acclimated to them, especially after the devices start improving their sleep quality. But for those resistant to using the devices, the pill could be an effective alternative. Ultimately, the more treatment options, the better, said Zee. Whether you use a CPAP machine, a pill or something else, treating sleep apnea can improve 'just about everything,' Combs said. One of his favorite studies, he said, was a small one from 2013 that found that golfers who treated their sleep apnea with a CPAP machine tended to perform better at the game — the implication being that they were more rested. 'It makes a huge difference,' Combs said. This article originally appeared in

1st pill for obstructive sleep apnea could be around the corner

24-07-2025

Health

1st pill for obstructive sleep apnea could be around the corner

The first oral pill for obstructive sleep apnea (OSA) could be around the corner after pharmaceutical company Apnimed Inc. reported positive results from its stage III clinical trial. Currently, many people diagnosed with OSA patients require a machine that covers their nose or both the nose and mouth during sleep and delivers air through a mask to help keep their airways open. Apnimed's lead candidate AD109 showed "clinically meaningful and statistically significant reductions" in airway obstruction after 26 weeks, the company said in a press release. AD109, a once-a-day pill, is a neuromuscular modulator that increases upper airway muscle tone, which is how contracted the muscles are in the upper airway. OSA patients treated with the medication saw a nearly 50% reduction in the severity from baseline at week 26, compared to 6.8% of those in the placebo group. The reduction was "significant" at the end of the study period, which concluded at 51 weeks. At the end of the trial, nearly 23% of participants saw "complete disease control." The results were part of Apnimed's 12-month study looking at the safety and efficacy of AD109 in adults with mild, moderate and severe OSA. AD109 was well-tolerated among participants with only mild or moderate adverse events. Which was consistent with prior studies, according to Apnimed. No serious adverse events were reported in the trial. "With two large Phase 3 studies now demonstrating a consistent and significant efficacy profile for AD109, we are closer to delivering the first oral pharmacotherapy for over 80 million U.S. adults with OSA," Dr. Larry Miller, CEO of Apnimed, said in a statement. "Given the scale of unmet need in OSA, where the majority of patients remain untreated, we believe AD109, as a simple once-daily oral drug, has the potential to expand and reshape the treatment landscape, which would represent a significant commercial opportunity for Apnimed." OSA is a sleep disorder in which the airways become narrowed or blocked while sleeping, causing breathing to pause, according to MedlinePlus. Soon after falling asleep, people experience loud and heavy snoring. The snoring is often interrupted by a long silent period during which breathing stops and then followed by a loud snort and gasp as the patient attempts to breathe. This can cause excessive daytime sleepiness and affect quality of life, mental well-being and cardiovascular health. In addition to a CPAP machine, there are lifestyle changes that people with sleep apnea can make including avoiding alcohol or medications that cause drowsiness and losing excess weight. Recently, the U.S. Food and Drug Administration (FDA) expanded approval of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity. The clinical trial did examine patients with a wide range of "weight classes" and did not see differences in efficacy based on weight. Apnimed plans to file a New Drug Application with the FDA in early 2026, according to Miller.

New York Times

23-07-2025

Health
New York Times

A Pill for Sleep Apnea Could Be on the Horizon

Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics

Business Upturn

16-07-2025

Health
Business Upturn

Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics

By GlobeNewswire Published on July 16, 2025, 22:00 IST New York, USA, July 16, 2025 (GLOBE NEWSWIRE) — Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics | DelveInsight The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT), AI-powered applications, and smart wearables are transforming the diagnostic landscape by making it more accessible and user-friendly. These innovations not only reduce the dependency on traditional sleep labs but also facilitate earlier diagnosis and timely intervention. As a result, more patients are entering the treatment pathway, supporting both improved clinical outcomes and sustained market expansion. DelveInsight's 'Obstructive Sleep Apnea Pipeline Insight 2025' report provides comprehensive global coverage of pipeline obstructive sleep apnea therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obstructive sleep apnea pipeline domain. Key Takeaways from the Obstructive Sleep Apnea Pipeline Report DelveInsight's obstructive sleep apnea pipeline report depicts a robust space with 12+ active players working to develop 14+ pipeline obstructive sleep apnea drugs. active players working to develop pipeline obstructive sleep apnea drugs. Key obstructive sleep apnea companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science , and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape. and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape. Promising pipeline obstructive sleep apnea therapies, such as Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others, are in different phases of obstructive sleep apnea clinical trials. and others, are in different phases of obstructive sleep apnea clinical trials. In June 2025 , Innovent Biologics, Inc. announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of Mazdutide , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2). , announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with and obesity (BMI ≥ 28 kg/m2). In April 202 5, Apnimed announced that the first patient had been dosed in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, SASS-001 , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi). 5, announced that the in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi). In April 2025 , Shionogi & Co., Ltd. announced that it had entered into an agreement with Apnimed, Inc. for the introduction of sulthiame * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed. , Shionogi & Co., Ltd. announced that it had entered into an with for the introduction of * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed. In April 2025 , Apnimed announced that it had acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame , a differentiated carbonic anhydrase inhibitor, in the broad field of sleep apnea and sleep-related breathing diseases, from D esitin Arzneimittel GmbH . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS). , announced that it had to develop and commercialize , a differentiated carbonic anhydrase inhibitor, in the broad field of and sleep-related breathing diseases, from D . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS). In April 2025 , Incannex Healthcare Inc. announced that the Company has completed Phase II patient enrollment in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality. , announced that the Company has in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality. In January 2025, Mineralys Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had cleared the Company's Investigational New Drug (IND) Application for a Phase II clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. Request a sample and discover the recent advances in obstructive sleep apnea drugs @ Obstructive Sleep Apnea Pipeline Report The obstructive sleep apnea pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Obstructive Sleep Apnea drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obstructive sleep apnea clinical trial landscape. Obstructive Sleep Apnea Overview Obstructive sleep apnea (OSA) is a sleep disorder marked by repeated episodes of partial or complete blockage of the upper airway during sleep. These episodes cause drops in oxygen levels and frequent awakenings, resulting in fragmented, poor-quality sleep. Common signs include loud snoring, witnessed pauses in breathing, and excessive daytime sleepiness. OSA can have wide-ranging health effects, impairing cardiovascular health, behavior, quality of life, and even driving safety. While other types of sleep-disordered breathing, such as central sleep apnea, upper airway resistance syndrome, and obesity hypoventilation, share some features with OSA, they are distinct conditions and will be discussed separately. The symptoms of OSA vary and can severely impact day-to-day functioning. These include persistent daytime drowsiness, loud snoring, gasping or choking during sleep, morning headaches, dry mouth or sore throat upon waking, difficulty concentrating, mood disturbances such as irritability or depression, high blood pressure, and reduced libido. These manifestations can greatly affect both physical well-being and overall life quality. The underlying cause of OSA involves upper airway obstruction during sleep, mainly due to negative pressure that causes the airway to collapse during inhalation. A key area of concern is the narrowing of the airway in the retropalatal region during exhalation. Obesity is a significant risk factor, with a higher body mass index (BMI) linked to greater airway narrowing. Both structural factors (like airway size) and neuromuscular control contribute to this condition. Understanding how airflow interacts with pressure in collapsible airways is vital to grasping the mechanics of OSA. Additional anatomical and physiological factors also influence the severity of the disorder. Managing OSA requires a personalized and multifaceted approach. For mild-to-moderate cases, lifestyle changes, such as losing weight, maintaining good sleep habits, and avoiding alcohol and sedatives, are important first steps. Continuous positive airway pressure (CPAP) therapy is the most effective treatment for moderate-to-severe OSA, though adherence can be difficult. Alternatives like oral appliances, especially mandibular advancement devices, may help in less severe cases. Surgical options, including uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (HNS), may be considered for more severe or treatment-resistant cases. In rare, severe situations, a tracheostomy may be necessary, particularly for patients with significant comorbidities. Ultimately, the best outcomes are achieved through an individualized treatment plan that may combine several strategies to relieve symptoms, improve sleep quality, and enhance overall health. Find out more about obstructive sleep apnea drugs @ Obstructive Sleep Apnea Treatment A snapshot of the Pipeline Obstructive Sleep Apnea Drugs mentioned in the report: Drugs Company Phase MoA RoA AD109 Apnimed III Adrenergic uptake inhibitors; Cholinergic receptor antagonists; Muscarinic receptor antagonists Oral Retatrutide Eli Lilly and Company III Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists Subcutaneous IHL-42X Incannex Healthcare Ltd II/III Cannabinoid receptor CB2 agonists; Carbonic anhydrase inhibitors Oral Lorundrostat Mineralys Therapeutics Inc. II Aldosterone synthase inhibitors Oral Sulthiame Apnimed II Carbonic anhydrase inhibitors Oral SASS-001 Shionogi Apnimed Sleep Science II Purinergic P2X3 receptor antagonists Oral Learn more about the emerging obstructive sleep apnea therapies @ Obstructive Sleep Apnea Clinical Trials Obstructive Sleep Apnea Therapeutics Assessment The obstructive sleep apnea pipeline report proffers an integral view of the emerging obstructive sleep apnea therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Obstructive Sleep Apnea Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists : Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists Key Obstructive Sleep Apnea Companies : Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others. : Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others. Key Obstructive Sleep Apnea Pipeline Therapies: Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others. Dive deep into rich insights for new obstructive sleep apnea treatments, visit @ Obstructive Sleep Apnea Drugs Table of Contents 1. Obstructive Sleep Apnea Pipeline Report Introduction 2. Obstructive Sleep Apnea Pipeline Report Executive Summary 3. Obstructive Sleep Apnea Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Obstructive Sleep Apnea Clinical Trial Therapeutics 6. Obstructive Sleep Apnea Pipeline: Late-Stage Products (Pre-registration) 7. Obstructive Sleep Apnea Pipeline: Late-Stage Products (Phase III) 8. Obstructive Sleep Apnea Pipeline: Mid-Stage Products (Phase II) 9. Obstructive Sleep Apnea Pipeline: Early-Stage Products (Phase I) 10. Obstructive Sleep Apnea Pipeline Therapeutics Assessment 11. Inactive Products in the Obstructive Sleep Apnea Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Obstructive Sleep Apnea Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the obstructive sleep apnea pipeline therapeutics, reach out @ Obstructive Sleep Apnea Therapeutics Related Reports Obstructive Sleep Apnea Epidemiology Forecast Obstructive Sleep Apnea Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted obstructive sleep apnea epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Obstructive Sleep Apnea Market Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., among others. Sleep Apnea Market Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others. Sleep Apnea Pipeline Sleep Apnea Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others. Sleep Apnea Diagnostic Devices Market Sleep Apnea Diagnostic Devices Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea diagnostic devices companies, including Natus Medical Incorporated., SOMNOmedics GmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited., ActiGraph, LLC., Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A., among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.